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Abstract
Background Hereditary hemorrhagic telangiectasia is a
genetic disease characterized by teleangiectasias involving
virtually every organ. There are limited data in the litera-
ture regarding the natural history of liver vascular mal-
formations in hemorrhagic telangiectasia and their
associated morbidity and mortality.
Aim This prospective cohort study sought to assess the
outcome of liver involvement in hereditary hemorrhagic
telangiectasia patients.
Methods We analyzed 16 years of surveillance data from
a tertiary hereditary hemorrhagic telangiectasia referral
center in Italy. We considered for inclusion in this study
502 consecutive Italian patients at risk of hereditary hem-
orrhagic telangiectasia who presented at the hereditary
hemorrhagic telangiectasia referral center and underwent a
multidisciplinary screening protocol for the diagnosis of
hereditary hemorrhagic telangiectasia. Of the 502 individ-
uals assessed in the center, 154 had hepatic vascular mal-
formations and were the subject of the study; 198 patients
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DOI 10.1007/s10620-011-1585-2with hereditary hemorrhagic telangiectasia and without
hepatic vascular malformations were the controls. Addi-
tionally, we report the response to treatment of patients
with complicated hepatic vascular malformations.
Results The 154 patients were included and followed for a
median period of 44 months (range 12–181); of these, eight
(5.2%) died from VM-related complications and 39 (25.3%)
experienced complications. The average incidence rates of
death and complications were 1.1 and 3.6 per 100 person-
years, respectively. The median overall survival and event-
freesurvivalafterdiagnosiswere175and90 months,respec-
tively. The rate of complete response to therapy was 63%.
Conclusions This study shows that substantial morbidity
and mortality are associated with liver vascular malfor-
mations in hereditary hemorrhagic telangiectasia patients.
Keywords Hereditary hemorrhagic telangiectasia 
Liver vascular malformations  Heart failure 
Portal hypertension  Gastrointestinal bleeding 
Liver transplantation
Introduction
Hereditary hemorrhagic telangiectasia (HHT), or Rendu-
Osler-Weber disease, is a genetic disorder that is charac-
terized by widespread cutaneous, mucosal and visceral
telangiectasias and is reported to affect between one and
two of every 10,000 people in the general population [1–6].
The clinical presentation of HHT varies based on the
number, type and location of either the telangiectasias or
the larger vascular malformations (VMs). The clinical
criteria for diagnosing HHT, known as the Curac ¸ao criteria,
have been established by a panel of experts [7]. Most
patients with HHT have mutations in one of the two known
disease-related genes: either endoglin (ENG, HHT1) [8, 9]
or activin A receptor type II-like 1 (ACVRL1, HHT2) [10,
11], both of which are involved in the TGFß pathway.
Mutations in the SMAD4 gene can cause the development
of a rare syndrome that combines the symptoms of juvenile
polyposis and HHT [12]. Recently, using linkage analysis,
additional genes have been found at the predicted loci on
chromosome 5 (HHT3) and on chromosome 7 (HHT4) [13,
14]. Genetic testing is available on a clinical basis.
Hepatic VMs are found in 41–74% of HHT-affected
subjects [15, 16]. The prevalence of the hepatic VMs that
are unique to HHT varies between 1/7,000 and 1/12,500
and they are thus more frequent than liver involvement in
either Wilson disease or other liver vascular disorders, such
as Budd-Chiari. The prevalence of hepatic VMs prevalence
depends substantially on which genotype of HHT is pres-
ent; genotype–phenotype correlation studies have demon-
strated that hepatic VMs are signiﬁcantly more frequent in
patients who had the HHT2 genotype than in patients who
had the HHT1 genotype [17–21]. Some studies have sug-
gested that truncating mutations have a more dramatic
effect on HHT phenotype than missense mutations have on
HHT phenotype [22], with a greater frequency of nose-
bleeds, telangiectases and pulmonary VMs found in
patients who have HHT with a truncating mutation [18].
The penetrance of most of the clinical features of HHT
depends on a patient’s age, but the effect of age is more
pronounced for hepatic VMs; according to a study of a
large screening series, the mean age of patients who had
hepatic VMs was 52 years old [15]; and symptoms of
hepatic VMs generally do not occur before a patient
reaches age 50 [18]. Previous data show a strong and sig-
niﬁcant predominance of hepatic VMs in females who have
HHT, both for asymptomatic and symptomatic lesions with
a male/female ratio varying from 1/2 to 1/4.5; therefore,
the expressivity of HHT in the liver is likely dependent on
a patient’s sex [18, 23]. Studies have also hypothesized that
hormones modify the HHT phenotype [24].
The form of hepatic VMs ranges from small telangiec-
tasias to large arteriovenous malformations and can dif-
fusely involve the liver [25]. There are three types of
intrahepatic shunting: hepatic artery to portal vein, hepatic
artery to hepatic vein, and portal vein to hepatic vein. These
three shunt types are often concomitant and can lead to the
following, possibly coexistent, complications: high-output
cardiac failure (HOCF), portal hypertension, biliary ische-
mia, encephalopathy and mesenteric ischemia [23, 25–28].
HOCF caused by hepatic AVMs may be further compli-
cated by secondary pulmonary hypertension; when this
happens, an appropriate assessment must be taken because
pulmonary hypertension represents a relative contraindica-
tion to the embolization of pulmonary VMs [29].
Based on available data, pregnancy is suspected as a
potential precipitating factor that leads to complications
caused by hepatic VMs in HHT patients. Nonetheless,
whereas a study of 262 pregnancies by 111 HHT-affected
women found that 1% of the pregnancies resulted in either
severe complications or death that could be attributed to
pulmonary VMs [30], only nine anecdotal reports exist of
severe complications occurring during pregnancy and
related to hepatic VMs in HHT [31].
Thus far, data concerning the natural history of liver
VMs in HHT are lacking [25, 32]. These data should ide-
ally be derived from patients undergoing a systematic
screening protocol of subjects at risk of HHT to capture the
complete spectrum of hepatic VMs [3, 25, 32].
These criteria are fulﬁlled by the present prospective
study which aimed to evaluate the outcome of liver VMs in
HHT patients in terms of overall survival and event-free
survival. We also evaluated responses to treatment of HHT
patients who exhibited symptoms of liver VMs.
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We conducted a longitudinal, prospective cohort study at a
tertiary HHT referral center. Our study considered 502
consecutive Italian patients (231 males, 272 females, mean
age 38.7, range 3–88, median 41 ± 19) at risk of HHT
(i.e., with either a personal/familial history of nosebleeds or
mucocutaneous telangiectases or visceral vascular malfor-
mations or a ﬁrst degree relative affected according to the
Curac ¸ao criteria [7]). All of these patients underwent a
multidisciplinary screening protocol to diagnose HHT
between April 1992 and April 2007. Pertinent follow-up
records until October 2008 were evaluated. The Curac ¸ao
criteria were applied to deﬁne the HHT affection status [7].
Abdominal Doppler ultrasound (US) was used to diagnose
liver VMs.
Inclusion Criteria
We included patients with either clinical diagnosis of HHT
(two-possible- or three-deﬁnite-Curacao criteria) or genetic
diagnosis of HHT and the presence of liver VMs on
Doppler US, as diffuse hepatic VMs which are unique to
HHT (and with their inherent Doppler US presentation as
previously described [15, 33]).
Exclusion Criteria
We excluded subjects without HHT and patients with HHT
but without liver VMs at initial screening.
Control Group
Patients with HHT without liver VMs at initial screening
were used as the control group to maximize similarity
between study population and controls.
Screening Protocol
Our screening protocol was approved by the Institutional
Review Board. All patients (or the parents of patients
\18 year old) who took part in the study provided written
informed consent.
Clinical Assessment
Patients underwent an initial clinical assessment and peri-
odic checkups at the referral center, according to the time
schedule speciﬁed in the section Follow-up. Data collection
focused on the symptoms and the clinical signs thought to
be related to liver VMs and their complications. If a patient
had cardiac failure we determined whether other causes of
HOCF were present (e.g., thyroid disease). Each checkup
included a complete physical examination and an
electrocardiogram.
Complications of liver involvement were deﬁned
according to international consensus [25] and were asses-
sed on the basis of a multidisciplinary approach including
clinical, biochemical and instrumental evaluations when
appropriate. Complications included the following: HOCF
(with fatigue, dyspnea associated with ascites and/or limb
edema; all patients were classiﬁed according to the New
York Heart Association [NYHA] functional classiﬁcation),
complicated portal hypertension (with ascites and/or gas-
trointestinal bleeding), encephalopathy, cholangitis and
mesenteric angina [25, 26, 32, 34, 35]. The etiology of
ascites (whether derived from HOCF or portal hyperten-
sion) was established on the basis of clinical, laboratory
and instrumental data.
Laboratory Assessment
At the time of patient enrollment, blood samples were taken
for DNA extraction and mutational analysis. Measured at
each checkup, we determined in each patient the following
parameters: hemoglobin, serum iron, ferritin, AST, ALT,
GGT, alkaline phosphatase, bilirubin, total protein, albu-
min, international normalized ratio (INR). Two parameters,
INR and albumin, were used to evaluate synthetic liver
functional efﬁciency. Abnormal values were expressed as
the fold difference relative to the upper limit of normal
(n 9 ULN). Serum markers related to current or past hep-
atitis C and/or B virus infection were collected at the time of
enrollment. Cirrhosis was diagnosed using internationally
accepted criteria, including history, clinical/laboratory
ﬁndings, and pertinent Doppler US ﬁndings [36].
Instrumental Assessment
As previously described, Doppler abdominal US scans
were performed during enrollment and during follow-up
visits [15, 37–39]. Based on the Doppler US ﬁndings, liver
VMs were classiﬁed according to their severity grades as
follows: minimal (0 to 1), moderate (2), severe (3), and
decompensated (4) [15, 37, 38]. Patients were diagnosed
with portal hypertension if the diameter of their portal vein
was either [13 mm or was associated with arterioportal
shunts or splenomegaly (deﬁned as craniocaudal diameter
[13 cm).
Patients with liver VMs underwent echocardiographic
examinations to evaluate cardiac function and morphology
both at the time of enrollment and during each checkup.
Using echocardiographic evaluation, we examined in each
patient the following parameters: cardiac index (l/min/m
2),
calculated as: cardiac output 9 [(p 9 d
2/4 9 VTI 9 car-
diac frequency)/body surface area], where d represents the
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123diameter of the left ventricular outﬂow tract and VTI rep-
resents the sub-aortic velocity time integral. In cases where
a patient suffered atrial ﬁbrillation, the cardiac index was
calculated using the average of at least ten cardiac cycles.
Right ventricular systolic pulmonary arterial pressure
(mmHg), was calculated as: [(4 9 the maximum velocity
of tricuspid regurgitant jet
2) ? mean right atrial pressure].
An upper GI endoscopy was performed if either GI
bleeding was suspected or if evaluation of portal hyper-
tension patients was required, with further investigation
[video capsule endoscopy (since 2001), colonoscopy]
undertaken on the basis of pertinent ﬁndings.
When necessary, we performed additional tests that
included the following: chest X-ray, computed tomography
nuclear magnetic resonance imaging, liver scintigraphy
(with 99 mTc sulfur colloid), angiography, right heart
catheterization, and portal pressure measurement (with a
hepatic venous pressure gradient) [25].
Follow-Up
Depending on the severity of liver VMs found in a patient,
we scheduled clinical and instrumental checkups for each
patient. The amount of time between each was determined
as follows: ﬁve years (for VM grades between 0 and 1),
three years (for VM grades of 2), two years (for VM grades
of 3), and between one month and one year (for VM grades
of 4 and depending on the patient’s speciﬁc clinical
condition). To avoid losing patients, we called patients
who missed their scheduled appointments to attempt to
reschedule. Furthermore, patients could elect to schedule a
follow-up for any reason that could potentially relate to
HHT.
The total number of follow-up months to the last check-
up was calculated for every patient.
Treatment
In patients with symptomatic liver involvement, we used
multidisciplinary, clinical, biochemical, and instrumental
approaches to correct the complications in a manner
independent of the procedure for grading the liver VMs.
Intense medical therapy was given to patients with HOCF
NYHA class II to IV (including, as clinically needed, salt
restrictions, diuretics, beta-blockers, digoxins, angiotensin-
converting enzyme inhibitors, antiarrhythmic agents, car-
dioversions, and radiofrequency catheter ablation). The
immediate goals of treating HOCF were to alleviate
symptoms and to stabilize hemodynamic condition [40].
Treatment of portal hypertension complications (e.g.,
ascites or bleeding from gastroesophageal varices) and
encephalopathy were undertaken as recommended in
cirrhotic patients. Antibiotics were administered for
cholangitis. Patients were also provided with supportive
care, which included, when required, either blood trans-
fusions or iron administration for purposes of both cor-
recting anemia and treating of the source of bleeding (e.g.,
either epistaxis or gastrointestinal bleeding) in actively
bleeding patients.
In patients who failed to respond to complication
treatments and exhibited a progressive worsening of their
clinical conditions, invasive treatments, which included
transarterial embolization of liver VMs and orthotopic liver
transplantation, were considered in order to eliminate
hepatic VMs.
Patient Outcomes
The primary end-point of the present study was death
related to a treated or untreated liver VM complication.
There were two secondary end-points. The ﬁrst was
grouped as clinical parameters, i.e., the development of
symptoms/signs of complicated liver VMs (HOCF com-
plicated portal hypertension with ascites and/or gastroin-
testinal bleeding, encephalopathy, cholangitis and
mesenteric angina, and, in general, any event related to
either mesenteric or systemic circulation, because the liver
has a unique hemodynamic relationship with both circu-
lations) and the need for treatment of liver VMs. The
second was biochemical, i.e., the development of chole-
stasis signs/symptoms. Patients with HHT but without liver
VMs at initial screening were used as a control group to
compare incidences of secondary end-points.
Response to therapy was deﬁned as stable asymptomatic
(where disappearance of symptoms/clinical signs of com-
plicated liver VMs and, in particular, if HOCF returned to
NYHA class I); stable but with ongoing symptoms (where
improvement, but not disappearance, of clinical signs and
symptoms and, in particular, if HOCF was downgraded to
NYHA class III or II); or progressive (if worsening or death
occurred despite treatment).
Statistical Analysis
Both cause-speciﬁc survival and time between the diag-
nosis of liver VMs and the development of symptoms or
death were estimated using the Kaplan–Meier method.
Univariate analysis of continuous variables was per-
formed using the Mann–Whitney rank sum test, and uni-
variate analysis of categorical variables was performed
using Fisher’s exact test (two-tailed). Differences were
considered statistically signiﬁcant when P\0.05, and
Bonferroni’s correction for multiple comparisons was used
for each end-point.
Statistical analyses were performed using SPSS (version
15; SPSS, Inc., Chicago, IL).
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Baseline Demographics
Patient demographics (for both screened and included
subjects) are shown in Fig. 1.
Baseline demographic, laboratory and radiological
characteristics of the 154 HHT subjects with liver VMs are
listed in Table 1. Altogether, 13 patients displayed symp-
toms during the initial examination (Tables 1 and 2).
The 154 patients were followed-up for a median period
of 44 months (range 12–181), accounting for a total of 731
person-years.
During follow-up, the grading of liver VMs remained
stable in 122 subjects (79%) and worsened in 32 (21%),
with two subjects shifting from grade 0.5 to 1 and two
subjects shifting to grade 2 from either grade 0.5 or grade
1, seven subjects shifting to grade 2 to 3, and ten shifting to
grade 4 (three from grade 2, seven from grade 3).
The 198 patients with HHT but without liver VMs
formed our control group (Fig. 1). The 198 controls were
followed-up for a median period of 42 months (range
11–179) accounting for a total of 836 person-years.
No subjects were lost to follow-up in both the patient
group and the control group.
Clinical Course and Outcome
Mortality
Eight (5.2%; seven females, one male, mean age at death
74, range 62–90) died of liver VM-related complications,
as detailed in Table 2. The average incidence rate of fatal
outcomes was 1.1 per 100 person-years (95% conﬁdence
interval [CI] 0.3–1.8). The median survival time after
diagnosis was 175 months (range 24–181 months, 95% CI
66–283) in the Kaplan–Meier analysis (Fig. 2a).
There were two deaths in the 13 patients (15%) who
were symptomatic at the baseline evaluation (patients 4 and
5 in Table 2), and there were six deaths in the 141 patients
(4%) who were asymptomatic at baseline (patients 17, 20,
23, 28, 34, and 35 in Table 2); this difference was not
statistically signiﬁcant (P = 0.28).
All eight patients who died had stage 4 liver VMs at
baseline (out of 23 patients who had stage 4 liver VMs; see
Fig. 1), which was a signiﬁcantly greater rate (P\0.001)
than in patients with other liver VMs stages between 0.5
and 3. Of the patients who died, one had HHT1, seven had
HHT2, and seven had missense mutations.
Five deaths occurred in the same pedigree.
Morbidity
Of the 154 patients, 39 (25.3%) had clinical events pos-
sibly related to liver VMs (Tables 2 and 3); after exclusion
of 13 (33%) subjects with symptoms related to VMs at
baseline, the remaining 26 (67%) developed symptoms
during follow-up, with an incidence rate of 3.6 events per
100 person-years (95% CI 2.2–4.9). The median event-free
survival was 90 months (range 10–181, 95% CI 44–135
months) (Fig. 2b).
The estimated median times to the development of
HOCF, atrial ﬁbrillation, portal hypertension, ascites and
GI bleeding were 58 (range 15–172), 88 (range 2–151), 41
(range 16–136), 72 (range 27–177) and 23 (range 2–90)
months, respectively.
The more common complications (listed as incidence
rates per 100 person-years) were as follows: HOCF (1.4,
95% CI 0.5–2.2); complicated portal hypertension (1.2,
95% CI 0.4–1.9); and GI bleeding (1.0, 95% CI 0.2–1.7).
In the control group, no patients had HOCF or portal
hypertension (due to liver VMs), which was signiﬁcantly
less frequent than in the study population (P = 0.009). No
control subject had ascites, encephalopathy, cholangitis, or
mesenteric angina (P = 0.009 for ascites; not signiﬁcant
for encephalopathy and mesenteric angina).
Fig. 1 Prevalence of hereditary hemorrhagic telangiectasia (HHT)
and liver vascular malformations (VMs) in the study population
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A potential precipitating factor for HOCF was found in
eight of 14 patients: anemia was found in seven patients
and evidence of steroid treatment was found in one.
Atrial Fibrillation
Atrial ﬁbrillation occurred in 12/154 patients with hepatic
VMs (1.6 incidence rate per 100 person-years, 95% CI
0.6–2.5). Two out of 198 controls had atrial ﬁbrillation, for
an incidence rate of 0.2 (95% CI 0.1–0.5) (P\0.001).
Of nine patients with paroxysmal atrial ﬁbrillation, eight
had a mean of six recurrences (range 2–15), and seven of
these eight patients developed chronic atrial ﬁbrillation
after a mean interval of 36 months (range 2–80). Two with
paroxysmal atrial ﬁbrillation did not develop HOCF after
16 and 74 months of follow-up, respectively.
Of the ten patients with chronic atrial ﬁbrillation,
arrhythmia preceded HOCF in six patients by a mean
interval of 45 months (range 6–88); in one patient, the
onsets of both arrhythmia and HOCF occurred simulta-
neously; in two, it followed HOCF by 38 and 59 months,
respectively; in one, HOCF had not developed at the
95-month follow-up.
Table 1 Baseline demographic, laboratory and instrumental imaging characteristics of 154 hereditary hemorrhagic telangiectasia (HHT)
patients with liver vascular malformations (VMs)
Demographics 13 patients symptomatic at
baseline
141 patients asymptomatic at
baseline
All 154 patients
Mean ± SD Range Mean ± SD Range Mean ± SD Range
Age (y) 51 ± 16 21–64 47 ± 15 7–82 48 ± 16 7–82
Sex 6 male, 7 female 41 male, 100 female 47 male, 107 female
Laboratory ﬁndings
a
Hb, g/dl 10.2 ± 1.8 7.0–13.1 12.23 ± 2.9 5.6–19.2 12.13 ± 2.1 5.6–19.2
AST (IU/l 9 ULN) 1.1 ± 0.3 1–2 1.0 ± 0.3 1–4 1.1 ± 0.3 1–4
ALT (IU/l 9 ULN) 1.2 ± 0.4 1–2 1.37 ± 0.4 1–4 1.3 ± 0.4 1–4
GGT (IU/l 9 ULN) 3.46 ± 3.1 1–10 1.32 ± 1.2 1–8 1.52 ± 1.2 1–10
Alk phosphatase (IU/l 9 ULN) 1.28 ± 0.4 1–2 1.0 ± 0.2 1–3 1.08 ± 0.2 1–3
Bilirubin (mg/dl; 9ULN) 1.15 ± 0.5 1–3 1.0 ± 0.1 1–3 1.02 ± 0.1 1–3
INR 1.03 ± 0.07 1–1.2 1.0 ± 0.1 1–2 1.03 ± 0.1 1–2
Albumin (g/dl) 3.98 ± 0.1 3.8–4.2 4.33 ± 0.2 2.9–4.8 4.30 ± 0.2 2.9–4.8
Doppler US and echocardiography
b
Hepatic artery
Inner diameter (mm) 11.3 ± 4.5 6.3–22 7.78 ± 3.2 5.1–17 8.18 ± 2.7 5.1–22
Resistance index 0.53 ± 0.08 0.40–0.68 0.55 ± 0.1 0.34–0.75 0.54 ± 0.1 0.34–0.75
Peak ﬂow velocity (cm/sec) 127.6 ± 35.1 77–210 106.0 ± 25.4 75–212 108.04 25.4 75–212
Portal vein
Inner diameter (mm) 11.4 ± 3.0 8–16 8.78 ± 2.7 6–21 8.9 ± 2.7 6–21
Mean ﬂow velocity (cm/sec) 17.0 ± 5.0 11–26 19.45 ± 4.6 8–33 18.90 ± 3.6 8–33
Hepatic vein
Inner diameter (mm) 10.3 ± 3.7 7–18 7.89 ± 2.2 5–17 8.16 ± 2.2 5–18
Peak ﬂow velocity (cm/sec) 37.0 ± 11.5 22–57 34.7 ± 7.4 20–76 35.2 ± 8.4 20–76
Focal nodular hyperplasia
Number 0.38 ± 0.6 0–2 0.15 ± 0.7 1–5 0.23 ± 0.6 0–5
Diameter (cm) 1.0 ± 1.7 0–5.2 0.76 ± 1.9 2.2–20.7 0.79 ± 2.5 0–20.7
Cardiac Index (l/min/m
2)
c 4.3 ± 1.0 2.9–10.7 3. 2 ± 0.2 2.7–10.1 3.3 ± 0.4 2.7–10.7
Pulmonary artery pressure (mmHg) 34.2 ± 9.2 24–50 27.10 ± 4.0 21–48 28.14 ± 6.0 21–50
Hb hemoglobin, GGT gammaglutamyltranspeptidase
a Eight patients were anti-HCV positive (5/8 HCV RNA positive); two patients were HBsAg positive and HBV DNA negative
b Nodularity of the liver surface was found on Doppler US in ﬁve patients; focal or diffuse dilatation of intrahepatic bile ducts was found in two
patients
c Measured in 145/154 at baseline
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Patient Age
a(y) Sex Liver
VMs
stage
a
HOCF Atrial
ﬁbrillation
Supraventricular
tachycardia
Portal
hypert
Ascites Encephalopathy GI
bleeding
Abdominal
angina
Outcome
13 7M 4 1 1 1 1
b Alive
26 2F 2 1
b Alive
37 9M 4 1
b 1 1 Alive
46 1F 4 1
b 1 1 Dead
56 4M 4 1 1
b Dead
67 9M 4 1 1
b Alive
74 9F 4 1 1
b Alive
86 4F 4 1
b Alive
95 7F 4 1
b 1 Alive
10 56 F 2 1
b Alive
11 39 F 4 1 1 Alive
12 64 M 2 1
b Alive
13 62 M 1 1
b Alive
14 73 M 3 1
b 1 Alive
15 22 F 4 1
b 1 1 Alive
16 69 F 4 1
b Alive
17 48 F 4 1 1
b Dead
18 48 F 4 1
b 1 1 1 1 Alive
19 36 F 4 1
b 1 1 Alive
20 59 F 4 1
b 1 1 Dead
21 69 F 3 1
b Alive
22 69 F 2 1
b Alive
23 74 F 4 1 1
b Dead
24 64 M 2 1 1 1
b Alive
25 31 M 3 1
b 1 Alive
26 69 F 4 1 1 1
b Alive
27 70 F 4 1
b 1 Alive
28 64 F 4 1
b 1 1 Dead
29 38 M 3 1
b
30 57 M 2 1
b Alive
31 49 M 2 1
b Alive
32 52 F 2 1
b Alive
33 58 M 3 1
b 1 Alive
34 82 F 4 1
b 1 Dead
35 82 F 4 1 1
b Dead
36 56 M 3 1 1
b Alive
37 62 F 3 1 1
b Alive
38 52 F 3 1
b Alive
39 39 F 2 1
b Alive
Total
c 14 (9) 12 (8) 4 (3) 16 (10) 13 (8) 2 (1) 15 (10) 1 (1) Alive
HOCF high-output cardiac failure
The ﬁrst 13 patients had symptoms at enrolment. Patient 37 had coexistent HCV-related compensated cirrhosis. Patient 18 had mild arterial
hypertension
a At diagnosis
b The clinically dominant feature, and which was the death cause in cases with adverse outcome
c Percentages in brackets (number of complications/154 pts) are rounded to the next integer for decimal points[0.5
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(mean number of episodes was 6; range 2–15) and was not
associated with HOCF in any case. No control had supra-
ventricular tachycardia (P = 0.36).
GI Bleeding
GI bleeding was due in all cases to upper GI telangiecta-
sias. Six of 198 (3%, with an incidence rate per 100 person-
years of 0.7, 95% CI 5.2–8.7) controls had GI bleeding; the
difference compared to the study population was not sig-
niﬁcant (P = 0.36).
Anemia
The 39 patients who had complications had a mean value
of hemoglobin at baseline of 11.4 (range 5.6–15.9) and of
7.1 (range 3.4–11.3) at the last checkup; in the 115
patients not exhibiting complications, the mean values of
hemoglobin at baseline were 12.12 (range 5.6–19.2) and
11.8 (range 5.4–16.6) at the last checkup. Differences
between the two groups of patients were not statistically
signiﬁcant.
Genotype
Genotype (available for 110 out of 154 HHT subjects with
liver VMs) showed an ENG (HHT1) mutation in 27 cases
(18%) and an ACVRL1(HHT2) mutation in 83 cases
(54%). Mutational analysis (available for 99 patients)
revealed a truncating mutation in 33 patients (21%), a
missense mutation in 44 patients (28%), an in-frame
deletion in 16 patients (10%), and a splicing mutation in six
patients (3%).
Estroprogestinics
Estroprogestinics were taken before liver VMs diagnosis
by 28 women for a mean of 32.3 months (range 1–96).
During follow-up, 14 women were found to have a mean
estroprogestinic intake of 28.7 months (range 1–74).
Pregnancies
A mean of 2.07 (range 1–9) pregnancies was recorded in
75 women before diagnosis. During follow-up, three
patients had two pregnancies each. Symptoms related to
Fig. 2 Overall survival (a) and
event-free survival (b) curves of
154 hereditary hemorrhagic
telangiectasia (HHT) subjects
with liver vascular
malformations (VMs)
Table 3 Analysis of clinical events by liver vascular malformations (VM) stage
Liver VMs
stage
a
HOCF Atrial
ﬁbrillation
Supraventricular
tachycardia
Portal
hypert ?
ascites
Portal
hypertension ?
GI bleeding
Encephalopathy GI
bleeding
Abdominal
angina
Total
0? 00 0 0 0 0 0 0 0
10 0 0 0 0 0 1 01
20 1 1 1 1 1 5 0 1 0
33 2 2 1 1 0 0 09
41 1 9 1 5 7 1 0 13 5
Total 14 12 4 7 9 2 6 1 55
HOCF high-output cardiac failure
a At baseline
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123complications involving liver VMs were not reported in
any of the 155 at-term pregnancies.
Response to Treatments
Appropriate treatment was intensively administered to
every patient showing liver VM-related complications. In
four patients (non-responders to previous intensive treat-
ments), transarterial embolization (in two) and liver
transplant (in two) were performed.
HOCF
Salt restriction and diuretics, beta-blockers, digoxin, and
angiotensin-converting enzyme inhibitors were used to
treat 14 cases of HOCF. Nine patients became stably
asymptomatic; there was no response, with progression to
death, in two. Staged HA embolization was attempted in
two cases of HOCF who were not responsive to previous
treatments and rejected from liver transplantation, with a
transient response in one case but eventual progression to
death in both.
Liver transplantation was performed in one patient with
HOCF who was not responsive to previous treatments. In
this patient, cardiac and pulmonary hemodynamic assess-
ments (echocardiography, right heart catheterization)
showed both right and left heart severe dilatation, a cardiac
index of 6.2 l/min/m
2, and pulmonary hypertension with a
pulmonary arterial systolic pressure of 55 mmHg. These
data, which had shown a progressive worsening over
1 year in spite of intensive medical treatment, together
with the lack of clinical response and persistence of cardiac
failure NYHA class III–IV, led to the decision of liver
transplantation. After 14 months following a successful
transplantation, the patient showed continued stability and
was symptom-free.
Arrhythmias
To treat atrial ﬁbrillation, antiarrhythmic agents (e.g.,
amiodarone and ﬂecainide), calcium channel blockers,
beta-blockers, digoxin or electrical cardioversion were
used.
Conversion to sinus rhythm was obtained in two patients
(16%) without HOCF. Partial response, as shown by
slowing of the ventricular rate, was found in the remaining
10/12 patients, including the three patients in which atrial
ﬁbrillation presented with or after HOCF. Conversion to
sinus rhythm was obtained in the 2/198 controls who pre-
sented with atrial ﬁbrillation during follow-up.
To treat supraventricular tachycardia in four patients,
antiarrhythmic agents, beta-blockers, amiodarone, and
ﬂecainide were used. The treatment yielded a complete
response in three cases; one patient not responsive to
antiarrhythmics was successfully treated with RF ablation.
Complicated Portal Hypertension
Salt restriction and diuretics were used to treat ascites
associated with portal hypertension, with complete
response in four cases and lack of response and progression
to death in two cases. Liver transplantation was performed
in another case where the patient had refractory ascites, and
it proved successful, as the patient remained stable and
asymptomatic through the 56-month follow-up.
In six additional patients, GI bleeding was treated with
tranexamic acid, danazol, octreotide, and endoscopic
treatment with argon plasma coagulation. All patients
progressed to a stable asymptomatic condition.
GI Bleeding
In nine patients with GI bleeding associated with portal
hypertension, beta-blockers/octreotide, endoscopic treat-
ment with argon plasma coagulation of telangiectases, or
surgery (gastrectomy) were used. After treatment, six
patients were stable and asymptomatic, one was stable but
with ongoing symptoms, and two eventually died.
Abdominal Angina
One patient was treated with analgesics, and the patient
became stable but exhibited ongoing symptoms. HA-staged
embolization was then attempted, which similarly yielded a
stable patient with ongoing symptoms.
Encephalopathy
Encephalopathy was successfully treated in two patients
with lactulose and antibiotics.
Outcome of Treatments
The outcome of treatments in 55 complications observed
in 39 patients (Table 3) included: complete response
with stable condition in 35 (63.7%), partial response with
ongoing symptoms in 12 (21.8%), and no response (with
progression to death) in eight (14.5%).
Among the 15 complications occurring in the 13 patients
who were symptomatic at baseline, treatments yielded ﬁve
complete responses (33%), compared with 30 complete
responses (75%) in 40 complications occurring in 26
patients who were asymptomatic at baseline. Response to
2174 Dig Dis Sci (2011) 56:2166–2178
123treatment in this latter group proved signiﬁcantly better
(P = 0.01).
Changes in liver VM grading after treatment were not
observed in any of the treated patients.
Discussion
To date, data concerning the natural history of liver
involvement in HHT, derived from a longitudinal cohort
study, are lacking. However, such data could clearly have a
substantial impact on the clinical management of HHT.
The key ﬁnding of this large cohort study is to provide the
ﬁrst clear-cut evidence regarding the progression and out-
come of liver VMs in HHT patients, with event rates of 3.6
and 1.1 per 100 person-years, respectively.
The strengths of the study include (1) the potential to
conﬁrm that HOCF represents the predominant complica-
tion associated with HHT and that HOCF accounts for half
of hepatic VM–associated fatalities [41]; (2) arrhythmias
emerged as an important complication of hepatic VMs; (3)
our ﬁnding that all patients who died had stage 4 liver VMs
at baseline, which was a signiﬁcantly higher rate when
compared with patients with other liver VM stages, clearly
deﬁnes a patient subgroup at high risk for poor outcome,
who need the most intensive clinical management; (4) our
study allowed us to evaluate patient’s response to treatment.
With respect to patient response to therapy for liver com-
plications, 63% of patients had a complete response, and
21% of patients had a partial response; these high response
rates demonstrate that caution should be exercised when
considering major treatment methods, particularly emboli-
zation, which is not only risky but also palliative [25, 32];
and (5) the 90 month interval between the diagnosis and the
onset of symptoms observed in the present cohort is the time
span in which potentially effective preventive measures
could prevent or slow the course of the disease.
A limitation of the present study, as is usual in natural
history studies, is that recruitment consecutively included
either asymptomatic or symptomatic subjects and who
were likely to fall in different disease stages. To estimate
the lead-time bias in the interpretation of survival results,
we also provided the absolute mortality rates in the patients
who were symptomatic or asymptomatic at the diagnosis.
The lack of statistical signiﬁcance in the difference
between the absolute mortality rates in the symptomatic
patients compared to the absolute mortality rates of
asymptomatic patients at diagnosis (15 vs. 4%) actually
translates to a non signiﬁcant lead-time bias in the present
study.
Previous studies regarding liver VMs in HHT consist of
anecdotal reports, cross-sectional studies [15, 16, 28, 37,
38] dealing with the prevalence of hepatic involvement in
HHT, case series including only symptomatic patients [26],
and expert reviews [23, 27, 41].
In our study cohort, we found 154 patients with HHT
and liver VMs by systematically screening subjects at risk
for HHT; therefore, our participants provide an adequate
representation of the entire spectrum of patients who have
liver VMs. This is conﬁrmed by the distribution of liver
VMs stage shown in Fig. 1. The epidemiological scenario
depicted by our study shows marked differences from what
was previously hypothesized on the basis of prior reports,
though these reports were not dealing with natural history
[23, 26, 27].
Because this study included patients with chronic car-
diac overload due to liver VMs, we considered noteworthy
every cardiac event, including isolated cardiac arrhythmias.
In fact, the signiﬁcant difference in arrhythmia rates
between subjects with liver VMs and control subjects
supports the hypothesis that arrhythmias in patients with
liver VMs are not purely coincidental and should be
approached with special caution.
In contrast to previous studies, complicated portal
hypertension occurred at a rate comparable to that of
HOCF, accounting for the other half of HHT-associated
fatalities. A reasonable hypothesis to explain the increased
incidence of complicated portal hypertensionis is that in the
past, this complication was misdiagnosed as cirrhosis [41].
We therefore recommend a close follow-up with timely
medical and/or endoscopic treatment of complications.
As previously noted in a case series [26], the hemor-
rhagic complications were not due to variceal bleeding but
were due rather to bleeding from GI telangiectasias. In our
study, GI bleeding events were collected even in the
absence of portal hypertension; these events were used as
covariates in the event-free survival analysis. The differ-
ence in GI bleeding rates between subjects with liver VMs
and control subjects (10 vs. 3%), even though it did not
reach statistical signiﬁcance, suggests that a link exists
between GI bleeding and liver VMs. Probably, when this
complication is associated with portal hypertension, mes-
enteric congestion due to portal hypertension triggers and
tends to maintain bleeding from GI telangiectasias, as
suggested by the fact that nine of our 15 patients who
experienced GI bleeding had portal hypertension.
An ominous complication associated with hepatic VMs
is bile duct ischemia, which can lead to cholangitis and bile
duct necrosis, which may result in the need for emergent
orthotopic liver transplantation [25, 42–44]. Notably,
despite the presence of anicteric cholestasis in one-third of
our patients, we detected no cases of cholangitis. Clinical
awareness of the presence and severity of liver VMs, as
determined by screenings, subsequent follow-ups, and
timely therapeutic interventions, may have helped reduce
the rate of this complication.
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abdominal angina and encephalopathy [23, 25, 41]. Finally,
we observed no adverse events related to liver VMs during
pregnancy .
Our data support the use of the follow-up schedule used
in the present study, with greater checkup frequency indi-
cated for patients with liver VM stage 4. Moreover, these
data suggest that Doppler US not only can accurately
diagnose and stage liver VMs [15, 28, 33, 38, 45, 46], but
also can provide prognostic indications of liver VMs.
These data further support the clinical utility of using this
technique to screen for liver VMs [25, 32].
The causes of treatment failures in the present series are
likely to be multifactorial (e.g., anemia and atrial dilata-
tion). To explain the treatment failure rate (14%), we
speculate that most of the patients live a far distance from
our center, which is a tertiary HHT referral center that
attracts patients from all over Italy, making it more difﬁcult
to supervise the clinical management of patients. The dif-
ﬁculty of supervising patients underscores the importance
of providing detailed instructions to local physicians caring
for HHT patients outside of the tertiary care referral center
to allow them to deal with both current and potential
complications in a timely manner.
The longitudinal series highlights a problem that is
commonly encountered in HHT patients with complicated
liver VMs (i.e., the treatment of atrial ﬁbrillation). Atrial
ﬁbrillation, which in the present series was associated with
HOCF in nine cases and heralded HOCF in six, when
occurring in the context of HHT with chronic cardiac
overload due to liver VMs, requires maximum effort to
obtain rhythm control, either via cardioversion or via
antiarrhythmic drugs, because arrhythmia can critically
reduce cardiac hemodynamic efﬁciency. However, it
should be noted that in these patients, substantial left atrial
enlargement is common, which reduces the success rate of
antiarrhythmic therapy. Moreover, in HHT patients, anti-
coagulation also presents difﬁculties because it can cause
bleeding increase due to telangiectasias. Therefore, in this
context, the heart rate control can be realistically consid-
ered a success because there is no clear evidence that
restoring sinus rhythm is superior to controlling rate in
reducing morbidity and mortality in patients with persistent
atrial ﬁbrillation and heart failure [40]. The clinical
importance of HOCF also highlights the importance of
treating conditions that can precipitate cardiac failure.
Thus, both aggressive correction of a patient’s anemia and
maximum efforts to treat a patient’s bleeding source should
be given to patients with predictors of severe outcome of
liver VMs. Additionally, in these patients, drugs that could
precipitate volume overload, such as steroids or IV ﬂuids,
should be avoided.
The data of our study do not present strong arguments
for screening asymptomatic individuals with HHT, because
we did not treat patients prior to the onset of symptoms,
and because all treatments performed in symptomatic
patients did not alter hepatic VM grade. However, the
signiﬁcantly better outcome seen in treatments given to the
subgroup of patients who were asymptomatic at baseline,
where hepatic VMs were diagnosed by Doppler US
screening, seems to provide a favorable argument for
screening for liver VMs. Altogether, identifying patient
conditions by the initial screening enables the early iden-
tiﬁcation of liver VM complications, and in particular of
cardiac decompensation, which is a key point for treatment
success [40]. Advantages provided by the prior recognition
of the condition have been similarly found in the case of
pulmonary VMs in HHT [30].
Past studies show the potential for preventive treatments
for hepatic VM complications regardless of whether HHT
is present. These studies suggest that, for cardiac overload,
either angiotensin-converting enzyme inhibitors or carve-
dilol could be used to prevent cardiac remodeling;
for portal hypertension, beta-blockers could prevent GI
bleeding from varices or from GI telangiectasias [47]. Anti-
angiogenic drugs, such as bevacizumab, which has induced
a reduction in liver VMs in a few anecdotal reports, should
be studied in controlled trials that involve patients who
exhibit predictors of a poor outcome [48, 49].
In conclusion, our study shows that the progression of
hepatic VMs occurs in a considerable number of cases. Our
study identiﬁes a patient subgroup at high risk for a poor
outcome; patients in this subgroup require the most inten-
sive forms of clinical management and surveillance.
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